Cingulate Goodwill and Intangible Assets 2021-2025 | CING

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cingulate goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cingulate goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231.3B
Amgen (AMGN)	$162.4B
Gilead Sciences (GILD)	$142.4B
Vertex Pharmaceuticals (VRTX)	$121.3B
Bristol Myers Squibb (BMY)	$92.4B
CSL (CSLLY)	$84B
GSK (GSK)	$76.9B
Regeneron Pharmaceuticals (REGN)	$61.7B
Alnylam Pharmaceuticals (ALNY)	$55B
Argenex SE (ARGX)	$42.2B
BioNTech SE (BNTX)	$26.5B
Royalty Pharma (RPRX)	$21.3B
Insmed (INSM)	$21.1B
Biogen (BIIB)	$19.4B
Incyte (INCY)	$15.2B
Illumina (ILMN)	$15.1B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.1B
BioMarin Pharmaceutical (BMRN)	$11.6B
Ascendis Pharma (ASND)	$11.3B
QIAGEN (QGEN)	$11.2B
Moderna (MRNA)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exelixis (EXEL)	$9.9B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.8B
Halozyme Therapeutics (HALO)	$7.4B